I will continue supporting efforts to empower the FDA to fast-track cheaper off-label drugs and pursue importation of lower-cost prescription alternatives from trading partners such as Canada.

However, more work is required on this front. We must continue empowering the FDA to fast-track cheaper off-label drugs, and we should pursue the importation of lower-cost alternatives from trading partners like Canada.

Higgins said policymakers must continue empowering the FDA to fast-track cheaper off-label drugs and should pursue importation of lower-cost alternatives from countries such as Canada.

Higgins: Republicans are Working to Lower Costs, Improve Health Care - Congressman Clay Higgins
secondary · other · model gpt-5.5

Higgins' official health care page says he supports marketplace competition, reducing unnecessary federal regulations, and encouraging development of life-saving drugs, devices, and therapies.

This shows a general public position consistent with drug competition and FDA deregulation, but it does not identify a concrete action on off-label drug fast-tracking or importation from Canada.

partial unknown

Health Care - Congressman Clay Higgins
secondary · model gpt-5.5 · confidence 78%

Congress.gov lists H.R.832 as sponsored by Rep. Chellie Pingree, referred to the House Energy and Commerce Subcommittee on Health, with status Introduced. CRS summarizes that it would require FDA to allow personal importation of prescription drugs from Canada in certain instances.

A directly relevant Canada prescription-drug importation bill was introduced during Higgins' later House service, but it did not advance beyond subcommittee and Higgins is not shown as sponsor; the bill had only one cosponsor.

never same_term

H.R.832 - Safe and Affordable Drugs from Canada Act of 2021
secondary · model gpt-5.5 · confidence 86%

FDA/HHS issued a final rule, effective November 30, 2020, implementing Section 804 importation programs to allow importation of certain prescription drugs from Canada when cost-savings and safety requirements are met.

The executive branch created a regulatory pathway for Canadian prescription-drug importation. This partially fulfills the importation portion of the promise, but it was not a Higgins-sponsored legislative action and did not address off-label fast-tracking.

partial unknown

Importation of Prescription Drugs, Final Rule, 85 FR 62094
secondary · model gpt-5.5 · confidence 90%

FDA authorized Florida's Section 804 drug importation program, calling it the first step toward Florida facilitating importation of certain prescription drugs from Canada, subject to further FDA review and safety obligations.

FDA later approved the first state importation program from Canada, indicating real progress on the importation prong. Implementation still required additional drug-specific approvals and reporting, so this is partial rather than full delivery.

partial later_term

FDA Authorizes Florida’s Drug Importation Program
secondary · model gpt-5.5 · confidence 91%

S.204 became Public Law 115-176 on May 30, 2018. CRS describes it as exempting certain unapproved investigational drugs for terminally ill patients from specified FD&C Act requirements.

This enacted law loosened access to unapproved investigational drugs, which is adjacent to FDA fast-track/access policy, but it did not fast-track cheaper off-label drugs. It is only weakly related to the promise.

partial unknown

S.204 - Right to Try Act of 2017
secondary · model gpt-5.5 · confidence 72%

The House passed S.204 by recorded vote, 250-169. The Clerk records Higgins (LA), Republican, Louisiana, as Not Voting.

Even on the adjacent FDA access bill that became law, Higgins did not cast a recorded supportive vote, weakening evidence that he personally advanced this promise.

never unknown

Roll Call 214, S.204 Right to Try Act
secondary · model gpt-5.5 · confidence 88%

The House passed H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act, 230-192. The Clerk records Higgins (LA), Republican, Louisiana, as Nay.

Higgins voted against a major lower-prescription-drug-cost bill. H.R.3 was not specifically an off-label or Canada-importation bill, but the vote cuts against a broad promise to support federal efforts to lower prescription costs.

never unknown

Roll Call 682, H.R.3 Elijah E. Cummings Lower Drug Costs Now Act
secondary · model gpt-5.5 · confidence 82%